Hydroxychloroquine and chloroquine are oral antimalarial drugs under investigation for prophylaxis and treatment of coronavirus disease 2019 (COVID-19). Additional benefit of using these drugs with azithromycin has been reported1 but not confirmed. Recently, internet searches for purchasing hydroxychloroquine and chloroquine increased dramatically, and instances of increased prescribing and commercial purchasing have been reported.2,3 We quantified changes in outpatient prescriptions of hydroxychloroquine, chloroquine, and azithromycin.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Shehab N, Lovegrove M, Budnitz DS. US Hydroxychloroquine, Chloroquine, and Azithromycin Outpatient Prescription Trends, October 2019 Through March 2020. JAMA Intern Med. Published online July 06, 2020. doi:10.1001/jamainternmed.2020.2594
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: